Incannex Healthcare Ltd ADR (NASDAQ:IXHL) — Market Cap & Net Worth
Market Cap & Net Worth: Incannex Healthcare Ltd ADR (IXHL)
Incannex Healthcare Ltd ADR (NASDAQ:IXHL) has a market capitalization of $38.01 Million ($38.01 Million) as of April 26, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #22889 globally and #4778 in its home market, demonstrating a 4.41% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Incannex Healthcare Ltd ADR's stock price $3.79 by its total outstanding shares 13973663 (13.97 Million).
Incannex Healthcare Ltd ADR Market Cap History: 2022 to 2026
Incannex Healthcare Ltd ADR's market capitalization history from 2022 to 2026. Data shows change from $39.13 Million to $56.31 Million (-28.10% CAGR).
Index Memberships
Incannex Healthcare Ltd ADR is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #651 of 976 |
|
NASDAQ Composite
IXIC
|
$38.14 Trillion | 0.00% | #2185 of 3165 |
Weight: Incannex Healthcare Ltd ADR's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Incannex Healthcare Ltd ADR Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Incannex Healthcare Ltd ADR's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
58.17x
Incannex Healthcare Ltd ADR's market cap is 58.17 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $39.13 Million | $540.17K | -$10.25 Million | 72.43x | N/A |
| 2023 | $64.84 Million | $1.01 Million | -$48.81 Million | 63.95x | N/A |
| 2024 | $29.62 Million | $17.97K | -$27.63 Million | 1648.97x | N/A |
| 2025 | $5.00 Million | $86.00K | -$46.88 Million | 58.17x | N/A |
Competitor Companies of IXHL by Market Capitalization
Companies near Incannex Healthcare Ltd ADR in the global market cap rankings as of April 26, 2026.
Key companies related to Incannex Healthcare Ltd ADR by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #498 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #505 globally with a market cap of $52.32 Billion USD ( CN¥357.54 Billion CNY).
- Zoetis Inc (NYSE:ZTS): Ranked #516 globally with a market cap of $51.50 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #573 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #498 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #505 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $52.32 Billion | CN¥56.05 |
| #516 | Zoetis Inc | NYSE:ZTS | $51.50 Billion | $116.87 |
| #573 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $41.94 |
Incannex Healthcare Ltd ADR Historical Marketcap From 2022 to 2026
Between 2022 and today, Incannex Healthcare Ltd ADR's market cap moved from $39.13 Million to $ 56.31 Million, with a yearly change of -28.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $56.31 Million | +1025.70% |
| 2025 | $5.00 Million | -83.11% |
| 2024 | $29.62 Million | -54.31% |
| 2023 | $64.84 Million | +65.71% |
| 2022 | $39.13 Million | -- |
End of Day Market Cap According to Different Sources
On Apr 24th, 2026 the market cap of Incannex Healthcare Ltd ADR was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $38.01 Million USD |
| MoneyControl | $38.01 Million USD |
| MarketWatch | $38.01 Million USD |
| marketcap.company | $38.01 Million USD |
| Reuters | $38.01 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Incannex Healthcare Ltd ADR
Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synth… Read more